The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats

Brain Research

Volumn 1133, Issue 1, 2007, Pages 110-114

  Rose, Sarah ^a   Ramsay Croft, Neil ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

6 OHDA lesioned rat; A2a antagonist; l Dopa; Parkinson's disease; Rotational behaviour; ST1535

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; APOMORPHINE; CARBIDOPA; LEVODOPA; OXIDOPAMINE; ST 1535; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENTIATION; EXPLORATORY BEHAVIOR; LOCOMOTION; LOW DRUG DOSE; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ADENINE; ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXPLORATORY BEHAVIOR; LEVODOPA; MALE; MOVEMENT; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; SYMPATHOLYTICS; TRIAZOLES;

RATTUS;

EID: 33846326820     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.10.038     Document Type: Article

References (32)

1. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
2. Bove J., Marin C., Bonastre M., and Tolosa E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46 (2002) 251-257
3. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., and Montastruc J.L. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 (2004) 733-746
4. Fenu S., Pinna A., Ongini E., and Morelli M. Adenosine A2A receptor antagonism potentiates l-dopa-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321 (1997) 143-147
5. Floran B., Gonzalez B., Floran L., Erlij D., and Aceves J. Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat. Eur. J. Pharmacol. 520 (2005) 43-50
6. Hauser R.A., and Schwarzschild M.A. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 22 (2005) 471-482
7. Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
8. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., McDermott M., Seibyl J., Weiner W., Musch B., Kamp C., Welsh M., Shinaman A., Pahwa R., Barclay L., Hubble J., LeWitt P., Miyasaki J., Suchowersky O., Stacy M., Russell D.S., Ford B., Hammerstad J., Riley D., Standaert D., Wooten F., Factor S., Jankovic J., Atassi F., Kurlan R., Panisset M., Rajput A., Rodnitzky R., Shults C., Petsinger G., Waters C., Pfeiffer R., Biglan K., Borchert L., Montgomery A., Sutherland L., Weeks C., DeAngelis M., Sime E., Wood S., Pantella C., Harrigan M., Fussell B., Dillon S., exander-Brown B., Rainey P., Tennis M., Rost-Ruffner E., Brown D., Evans S., Berry D., Hall J., Shirley T., Dobson J., Fontaine D., Pfeiffer B., Brocht A., Bennett S., Daigneault S., Hodgeman K., O'Connell C., Ross T., Richard K., and Watts A. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61 (2004) 1044-1053
9. Jankovic J. Parkinson's disease therapy: treatment of early and late disease. Chin. Med. J. Engl. 114 (2001) 227-234
10. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 20 Suppl. 11 (2005) S11-S16
11. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61 (2003) S32-S38
12. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 14 (2005) 729-738
13. Kanda T., Shiozaki S., Shimada J., Suzuki F., and Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 256 (1994) 263-268
14. Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci. Biotechnol. Biochem. 65 (2001) 1447-1457
15. Koga K., Kurokawa M., Ochi M., Nakamura J., and Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur. J. Pharmacol. 408 (2000) 249-255
16. Kurokawa M., Kirk I.P., Kirkpatrick K.A., Kase H., and Richardson P.J. Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release. Br. J. Pharmacol. 113 (1994) 43-48
17. Lane E.L., Cheetham S., and Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J. Pharmacol. Exp. Ther. 312 (2005) 1124-1131
18. Lane E.L., Cheetham S.C., and Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?. Exp. Neurol. 197 (2006) 284-297
19. Mandhane S.N., Chopde C.T., and Ghosh A.K. Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328 (1997) 135-141
20. Martinez-Mir M.I., Probst A., and Palacios J.M. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience. 42 (1991) 697-706
21. Minetti P., Tinti M.O., Carminati P., Castorini M., DiCesare M.A., DiSerio S., Gallo G., Ghirardi O., Giorgi F., Piersanti G., Bartoccini F., and Tarzia G. 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogs as A2a adenosine receptor antagonists: design, synthesis and pharmacological characterisation. J. Med. Chem. 48 (2005) 6887-6896
22. Mori A., and Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61 (2003) S44-S48
23. Nash J.E., and Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20 (2000) 7782-7789
24. Pinna A., Volpini R., Cristalli G., and Morelli M. New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur. J. Pharmacol. 512 (2005) 157-164
25. Rascol O., Brooks D.J., Korczyn A.D., DeDeyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342 (2000) 1484-1491
26. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
27. Schiffmann S.N., Jacobs O., and Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57 (1991) 1062-1067
28. Schiffmann S.N., Libert F., Vassart G., and Vanderhaeghen J.J. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci. Lett. 130 (1991) 177-181
29. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., and Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berlin) 147 (1999) 90-95
30. Silverdale M.A., Fox S.H., Crossman A.R., and Brotchie J.M. Potential nondopaminergic drugs for Parkinson's disease. Adv. Neurol. 91 (2003) 273-291
31. Stasi, M.A., Borsini, F., Varani, K., Vincenzi, F., Di Cesare, M.A., Minetti, P., Ghirardi, O., Carminati, P., 2006. ST1535: a preferential A2a adenosine receptor antagonist. Int. J. Neuropsychopharm. 9, 575-584.
32. Weiss S.M., Benwell K., Cliffe I.A., Gillespie R.J., Knight A.R., Lerpiniere J., Misra A., Pratt R.M., Revell D., Upton R., and Dourish C.T. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 61 (2003) S101-S106